{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:47:42Z","timestamp":1792079262198,"version":"4.4.0"},"reference-count":50,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2022,2,16]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n                    Lipoprotein(a) (Lp(a)) is a complex circulating lipoprotein, and increasing evidence has demonstrated its role as a risk factor for atherosclerotic cardiovascular disease (ASCVD) and as a possible therapeutic target. Lp(a) atherogenic effects are attributed to several potential mechanisms in addition to cholesterol accumulation in the arterial wall, including proinflammatory effects mainly mediated by oxidised phospholipids. Several studies have found a causal and independent relationship between Lp(a) levels and cardiovascular risk. Furthermore, several studies also suggest a causal association between Lp(a) levels and calcific aortic valve stenosis. Available lipid-lowering agents have at best moderate impact on Lp(a) levels. Among available therapies, antibody proprotein convertase subtilisin\/kexin type 9 inhibitors are the most effective in reducing Lp(a). Potent Lp(a)-lowering treatments that target\n                    <jats:italic>LPA<\/jats:italic>\n                    expression are under development. Lp(a) level measurement poses some challenges due to the absence of a definitive reference method and the reporting of Lp(a) values as molar (nanomoles per litre (nmol\/L)) or mass concentrations (milligrams per decilitre (mg\/dL)) by different assays. Currently, Lp(a) measurement is recommended to refine cardiovascular risk in specific clinical settings, that is, in individuals with a family history of premature ASCVD, in patients with ASCVD not explained by standard risk factors or in those with recurrent events despite optimal management of traditional risk factors. Patients with high Lp(a) levels should be managed with more intensive approaches to treat other modifiable cardiovascular risk factors. Overall, this review focuses on Lp(a) as an ASCVD risk factor and therapeutic target. Furthermore, it reports practical recommendations for Lp(a) measurement and interpretation and updated evidence on Lp(a)-lowering approaches.\n                  <\/jats:p>","DOI":"10.1136\/heartjnl-2021-320708","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T13:33:14Z","timestamp":1647264794000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target"],"prefix":"10.1136","volume":"109","clinical-trial-number":[{"clinical-trial-number":"nct04023552","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-9930","authenticated-orcid":false,"given":"Stefania Angela","family":"Di Fusco","sequence":"first","affiliation":[{"name":"Emergency Department, San Filippo Neri Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scicchitano","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital \u201cF Perinei\u201d, Altamura, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Alonzo","sequence":"additional","affiliation":[{"name":"Emergency Department, San Filippo Neri Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perone","sequence":"additional","affiliation":[{"name":"Rehabilitation Clinic \"Villa delle Magnolie\", Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Massimo","family":"Gulizia","sequence":"additional","affiliation":[{"name":"Cardiology Division, Garibaldi-Nesima Hospital, Garibaldi-Nesima Hospital, Catania, Italy"},{"name":"Heart Care Foundation, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, San Camillo Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Oliva","sequence":"additional","affiliation":[{"name":"De Gasperis Cardio Center, Niguarda Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Imperoli","sequence":"additional","affiliation":[{"name":"Emergency Department, San Filippo Neri Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"Emergency Department, San Filippo Neri Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2025101713252933000_109.1.18.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2010.07.002"},{"key":"2025101713252933000_109.1.18.2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R067314"},{"key":"2025101713252933000_109.1.18.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902604"},{"key":"2025101713252933000_109.1.18.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.10.1774"},{"key":"2025101713252933000_109.1.18.5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"2025101713252933000_109.1.18.6","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ Res"},{"key":"2025101713252933000_109.1.18.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)32756-1"},{"key":"2025101713252933000_109.1.18.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004406"},{"key":"2025101713252933000_109.1.18.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-021-01861-6","article-title":"The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg\/dL","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"2025101713252933000_109.1.18.10","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur Heart J"},{"key":"2025101713252933000_109.1.18.11","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"7","author":"Welsh","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2025101713252933000_109.1.18.12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025101713252933000_109.1.18.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005243222104"},{"key":"2025101713252933000_109.1.18.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"2025101713252933000_109.1.18.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"2025101713252933000_109.1.18.16","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvu107"},{"key":"2025101713252933000_109.1.18.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.08.006"},{"key":"2025101713252933000_109.1.18.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.524"},{"key":"2025101713252933000_109.1.18.19","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12136"},{"key":"2025101713252933000_109.1.18.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.113.000400"},{"key":"2025101713252933000_109.1.18.21","article-title":"Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis","volume":"108","author":"Kaiser","year":"2022","journal-title":"Heart"},{"key":"2025101713252933000_109.1.18.22","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M005769"},{"key":"2025101713252933000_109.1.18.23","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101713252933000_109.1.18.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"key":"2025101713252933000_109.1.18.25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001696","article-title":"Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study","volume":"11","author":"Parish","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"2025101713252933000_109.1.18.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.006"},{"key":"2025101713252933000_109.1.18.27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of Alirocumab on Lipoprotein(a) Over \u22651.5 Years (from the Phase 3 ODYSSEY Program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"},{"key":"2025101713252933000_109.1.18.28","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1250"},{"key":"2025101713252933000_109.1.18.29","article-title":"Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics","volume":"25","author":"Swerdlow","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2025101713252933000_109.1.18.30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): A call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"2025101713252933000_109.1.18.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912387"},{"key":"2025101713252933000_109.1.18.32","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304549"},{"key":"2025101713252933000_109.1.18.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31009-1"},{"key":"2025101713252933000_109.1.18.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239"},{"key":"2025101713252933000_109.1.18.35","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625"},{"key":"2025101713252933000_109.1.18.36","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101713252933000_109.1.18.37","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307983"},{"key":"2025101713252933000_109.1.18.38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosissup.2017.05.004","article-title":"Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity","volume":"30","author":"Pokrovsky","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"2025101713252933000_109.1.18.39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025101713252933000_109.1.18.40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025101713252933000_109.1.18.41","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"key":"2025101713252933000_109.1.18.42","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R061648"},{"key":"2025101713252933000_109.1.18.43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin Chem"},{"key":"2025101713252933000_109.1.18.44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2025101713252933000_109.1.18.45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2025101713252933000_109.1.18.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"2025101713252933000_109.1.18.47","first-page":"01417","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)","volume":"17","author":"Chakraborty","year":"2021","journal-title":"Atherosclerosis"},{"key":"2025101713252933000_109.1.18.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.12.037"},{"key":"2025101713252933000_109.1.18.49","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R051904"},{"key":"2025101713252933000_109.1.18.50","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304785"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2021-320708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:25:39Z","timestamp":1760732739000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2021-320708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,13]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/heartjnl-2021-320708"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2021-320708","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}